SMYD3 and head and neck squamous cell carcinoma: In addition to our recent report identifying SMYD3 as an epigenetic regulator of immune response in HPV-negative HNSCC12, these findings provide further biological rationale to therapeutically target SMYD3 in HPV-negative HNSCC.